Lates News

Each AI express news, Southwest Securities released a research report on Kang Chen Pharmaceutical (603590.SH) on April 24. The main points include: 1) The effectiveness of marketing capability building continues to show, and the market competitiveness of core products continues to improve continuously; 2) Focus on innovative research and development, continuously enriching the matrix of innovative varieties; 3) KC1086 has great market potential and successfully obtained the new drug clinical research permission from the US FDA. (Daily Economic News)